Data Insights

SC-291 by Sana Biotechnology for Microscopic Polyangiitis (MPA): Likelihood of Approval

SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Microscopic Polyangiitis (MPA). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SC-291 in Microscopic Polyangiitis (MPA)

Data Insights

SC-291 by Sana Biotechnology for Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Likelihood of Approval

SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Granulomatosis with Polyangiitis (Wegener's Granulomatosis). According...

Likelihood of Approval and Phase Transition Success Rate Model - SC-291 in Granulomatosis with Polyangiitis (Wegener's Granulomatosis)

Data Insights

SC-291 by Sana Biotechnology for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval

SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)....

Likelihood of Approval and Phase Transition Success Rate Model - SC-291 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)

Data Insights

SC-291 by Sana Biotechnology for Lupus Nephritis: Likelihood of Approval

SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - SC-291 in Lupus Nephritis

Data Insights

SC-291 by Sana Biotechnology for Systemic Lupus Erythematosus: Likelihood of Approval

SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SC-291 in Systemic Lupus Erythematosus

Data Insights

SC-291 by Sana Biotechnology for Non-Hodgkin Lymphoma: Likelihood of Approval

SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...

Data Insights

SC-291 by Sana Biotechnology for Marginal Zone B-cell Lymphoma: Likelihood of Approval

SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Marginal Zone B-cell Lymphoma. According to...

Data Insights

SC-291 by Sana Biotechnology for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to...

Data Insights

SC-291 by Sana Biotechnology for Follicular Lymphoma: Likelihood of Approval

SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...

Data Insights

SC-291 by Sana Biotechnology for Mantle Cell Lymphoma: Likelihood of Approval

SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...

Data Insights

SC-291 by Sana Biotechnology for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According...

Data Insights

SC-291 by Sana Biotechnology for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

SC-291 is under clinical development by Sana Biotechnology and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According...